| Document |
Document Title |
|
JP2014197984A |
To conduct asymmetric α-amination of aldehydes high-stereoselectively using peptide catalyst.This catalyst is composed of a peptide and a carrier, the peptide containing an amino acid represented by formula (SAA)-(AA)-(AA2) or (SAA1)-(S...
|
|
JP5576416B2 |
The invention relates to pharmaceutically acceptable salts of guanylhydrazone-containing compounds, for example, Semapimod. The invention also relates to pharmaceutically acceptable compositions comprising the salts and methods for their...
|
|
JP5562484B2 |
The present invention relates to flame retardant polymer compositions which comprise aminoguanidine phenylphosphinates and mixtures with additional flame retardants. The compositions are especially useful for the manufacture of flame ret...
|
|
JP5551755B2 |
A compound, having the formula: or a salt thereof.
|
|
JP5530427B2 |
Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are...
|
|
JP2014111634A |
To provide a novel compound for improving ecdysone receptor complex-based gene regulation system.There is provided a diacylhydrazine ligand compound represented by the following formula, where X and X' are independently O or S, A is an u...
|
|
JP5484065B2 |
There are described compounds of general formula (I) and isomeric forms thereof wherein n is 0, 1, 2 or 3, saturated or unsaturated; most preferably at least one of R1 to R5 represents halogen; at least one of R1, R2, R3, R4 and R5 is se...
|
|
JP5487692B2 |
The present invention provides a compound having a heterocyclic skeleton, which is represented by of the formula (I) : wherein R 1 and R 2 are the same or different and each is a lower alkyl group optionally having substituent(s), an ara...
|
|
JP5482088B2 |
A compound represented by the formula (1): wherein Ar represents an aromatic hydrocarbon group having 6 to 20 carbon atoms which may have a substituent, Ar' represents an aromatic hydrocarbon group having 6 to 20 carbon atoms which may h...
|
|
JP5341762B2 |
Liquid pesticide composition containing N-phenylsemicarbazone pesticide compounds The present invention relates to liquid pesticide compositions which contain at least one N-phenylsemicarbazone of the formula A wherein R1 and R2 are each...
|
|
JP5321856B2 |
An isoxazoline-substituted benzamide compound of formula (1) or a salt thereof: wherein A 1 , A 2 and A 3 independently of one another are carbon atom or nitrogen atom, G is benzene ring, etc., X is halogen atom, C 1 -C 6 haloalkyl, etc....
|
|
JP5291854B2 |
The present invention provides a method represented by Scheme 1: wherein X represents I, Br, Cl, alkylsulfonate, or arylsulfonate; Z represents optionally substituted aryl, heteroaryl or alkenyl; L represents hydrogen or a negative charg...
|
|
JP2013166706A |
To provide a purification method for obtaining a purified product of a phenylhydrazine-β-carboxylate compound (I) having little impurities by efficiently separating and removing impurities included in a crude product of the phenylhydraz...
|
|
JP5266499B2 |
The present invention provides a method represented by Scheme 1: wherein X represents I, Br, Cl, alkylsulfonate, or arylsulfonate; Z represents optionally substituted aryl, heteroaryl or alkenyl; L represents hydrogen or a negative charg...
|
|
JP5248783B2 |
Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compound...
|
|
JP5238159B2 |
The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding...
|
|
JP5207096B2 |
|
|
JP5186503B2 |
The invention relates to chlorine Guanabenz derivatives for treating prion-based diseases. More specifically, it relates to the use of the molecule of formula (I) wherein R = H or Cl and the phenyl group is at least substituted twice, or...
|
|
JP2013010740A |
To provide a new method for producing an isoxazoline compound and production intermediates thereof.The method for producing the isoxazoline compound represented by chemical formula includes: (1) producing a carbamic acid ester compound b...
|
|
JP5117377B2 |
Chemical compounds identified by in silico molecular modelling, and having an structure that allows the blocking of the phosphorylation event, through the interaction of such compounds with the phosphorylation domain or its milieu in the...
|
|
JP5095887B2 |
The present invention provides a synergistic insecticidal composition comprising as essential active ingredients a neuronal sodium channel antagonist and an arylpyrrole insecticide.Also provided are methods for synergistic insect control...
|
|
JP5093429B2 |
Ectoparasitic insect pest controllers for animals, containing hydrazine derivatives of the general formula (I) as the active ingredient, and methods for application of the same: (I) Äwherein A is (II), (III), (IV), (V) (wherein R<4> and...
|
|
JP5086072B2 |
The invention relates to pharmaceutically acceptable salts of guanylhydrazone-containing compounds, for example, Semapimod. The invention also relates to pharmaceutically acceptable compositions comprising the salts and methods for their...
|
|
JP5086635B2 |
Antibacterial compounds of formula (I) are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; treating bacterial infections by the a...
|
|
JP5053661B2 |
|
|
JP2012515750A |
The present invention relates to compounds of azapeptide or azapeptidomimetic type of formula (I): in which R1, R2, R3, X1, X2, X3, X4 and Y are as defined in claim 1, to pharmaceutical compositions containing them and to such compounds ...
|
|
JP4965428B2 |
It is intended to provide a novel free radical scavenger for removing active oxygen which is causative for various diseases in vivo and results in degradation and color fade-out in commercial products. A free radical scavenger which cont...
|
|
JP4902361B2 |
Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compound...
|
|
JP2012505836A |
The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions cau...
|
|
JP4891516B2 |
The present invention provides novel compounds and use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: Wherein X and Y are independently chosen fr...
|
|
JP4883296B2 |
An isoxazoline-substituted benzamide compound of formula (1) or a salt thereof: wherein A 1 , A 2 and A 3 independently of one another are carbon atom or nitrogen atom, G is benzene ring, etc., X is halogen atom, C 1 -C 6 haloalkyl, etc....
|
|
JP4860509B2 |
|
|
JP4815566B2 |
The present invention provides non-steroidal compounds of formula I which are selective modulators (i.e., agonist and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides phar...
|
|
JP4805916B2 |
Provided are compounds of Formula V and pharmaceutically acceptable salts thereof which may be useful for the treatment of cancer or other proliferative disorders.
|
|
JP4789509B2 |
|
|
JP4793976B2 |
The present invention relates to a production method of optically active hydrazine compound (IV), which includes reacting azo compound (II) with compound (III) in the presence of optically active compound (I). The present invention also ...
|
|
JP2011526280A |
The present invention relates to a process for the isomerization of the Z-isomer I-Z of a semicarbazone compound of the general formula (I) into its E-isomer I-E wherein the variables in formula (I) have the meanings as defined in the de...
|
|
JP4784803B2 |
Phenylalanine derivatives of the following formula and analogues thereof have an antagonistic activity to alpha 4 beta 7 integrin and a selectivity toward alpha 4 beta 1 integrin. They are used as therapeutic agents for various diseases ...
|
|
JP2011522067A |
Reaction products prepared from reactants including: (a) at least one compound of structural Formula (I): wherein R1 is selected from aryl and heteroaryl; X is selected from a direct bond, —O—, —S—, —NH—, alkylene, cycloalkyl...
|
|
JP2011140488A |
To provide a peptidomimetic compound which inhibits the NS3 protease of a flavivirus of hepatitis C virus (HCV).The compound is represented by formula (VI).
|
|
JP4696258B2 |
A process for preparing alkoxytriazolinones of general formula (1):in which R1 and R2 independently represent an alkyl group, an aryl group, an arylalkyl group or cycloalkyl group. The alkoxytriazolinones are prepared by reacting, in a f...
|
|
JP4673568B2 |
|
|
JP4647780B2 |
A method is provided for the transition metal-catalyzed arylation, or vinylation, of hydrazines, hydrazones, and the like. Additionally, the invention provides a conceptually novel strategy, the cornerstone of which is the transition met...
|
|
JP4641640B2 |
|
|
JP2010539204A |
Disclosed are compounds of formula (I) which are bradykinin B1 receptor (B1R) antagonists. These compounds are useful to treat diseases or relieve adverse symptoms associated with inflammation and pain. The invention encompasses novel co...
|
|
JP4578685B2 |
A compound of the formulawhere the substituents are defined in the specification and its pharmaceutically acceptable salts and prodrugs thereof useful as antagonists of vitronectin receptors.
|
|
JP2010248093A |
To provide an asymmetric reaction wherein an optically active proline derivative is used as a catalyst, an optically active proline derivative, and an organic molecular catalyst including the derivative.There are disclosed an asymmetric ...
|
|
JP4564786B2 |
|
|
JP4550286B2 |
Acylquanidines of the formulawherein the substituents are defined as in the specification which are antagonists of the vitronectin receptor and inhibitors of cell adhesion and bone resorption mediated by the osteoclasts.
|
|
JP4529016B2 |
|
